Arvinas (ARVN) Change in Receivables (2017 - 2026)
Arvinas (ARVN) posted quarterly Change in Receivables of $800000.0 for Q1 2026, up 115.09% year-over-year from $371929.8 in Q1 2025, and up 104.15% quarter-over-quarter from -$19.3 million in Q4 2025.
Powered by 
Analysis
Arvinas (ARVN) Change in Receivables (2017 - 2026) Analysis & Trends
Arvinas' Change in Receivables history runs 10 years deep, the most recent figure standing at $800000.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 115.09% year-over-year to $800000.0; the TTM figure through Mar 2026 stood at $1.4 million (up 250.0% YoY), while the FY2025 annual figure was -$4.7 million, down 182.46% from the prior year.
- Change in Receivables for Q1 2026 stood at $800000.0, up from -$19.3 million in the prior quarter.
- The five-year high for Change in Receivables was $19.8 million in Q3 2025, with the low at -$19.3 million in Q4 2025.
- The 5-year median for Change in Receivables is -$150000.0 (2022), against an average of -$942857.1.
- The sharpest annual moves came in 2022 and 2023: Change in Receivables plunged 1400.0% in 2022, then jumped 4000.0% in 2023.
- Arvinas' Change in Receivables stood at -$400000.0 in 2022, then plunged by 3825.0% to -$15.7 million in 2023, then jumped by 89.81% to -$1.6 million in 2024, then plunged by 1106.25% to -$19.3 million in 2025, then soared by 104.15% to $800000.0 in 2026.
- Business Quant data shows ARVN's Change in Receivables at $800000.0 in Q1 2026, -$19.3 million in Q4 2025, and $19.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - | 48.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 48.50 Mn |
| Mar 31, 2026 | 800,000.00 |
| Dec 31, 2025 | -19.30 Mn |
| Sep 30, 2025 | 19.80 Mn |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | -5.30 Mn |
| Dec 31, 2024 | -1.60 Mn |
| Sep 30, 2024 | 7.30 Mn |
| Dec 31, 2023 | -15.70 Mn |
| Sep 30, 2023 | 15.60 Mn |
| Jun 30, 2023 | 100,000.00 |
| Mar 31, 2023 | -1.00 Mn |
| Sep 30, 2022 | -400,000.00 |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | -15.00 Mn |
| Dec 31, 2021 | 13.10 Mn |
| Sep 30, 2021 | 1.90 Mn |
| Mar 31, 2021 | -1.00 Mn |
| Dec 31, 2020 | -1.44 Mn |
| Sep 30, 2020 | 2.44 Mn |